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software recently developed at NASA that is able to perform HF QRS analysis in real
time on a beat-to-beat basis. Results. The mean number of HF QRS leads (out of 12)
containing reduced amplitude zones (RAZs) of at least moderate severity was 8.4 + 2.1
in the cardiomyopathy patients versus 2.6 + 2.4 in the healthy controls (P<0.001). In addi-
tion, an HF QRS ECG scoring system that takes into consideration both the total number
of RAZs and the clustering of RAZs together in adjacent leads was 93.1% sensitive and
89.7% specific for identifying cardiomyopathy. The total amplitude of the HF QRS com-
plexes, as measured by summed root mean square voltages (RMSVs), also differed
between the individuals with versus without cardiomyopathy (35.9 + 12.1 vs. 43.8 + 15.8
microvolts respectively, P<0.02), although RMSV was less effective in distinguishing the
two groups than were RAZ scores because of large inter-subject variability in RMSV. In
the cardiomyopathy group, neither RAZ scores nor RMSVs directly correlated with
echocardiographic EF. Conclusion. 12-lead HF QRS ECG employing RAZ analysis is a
simple, sensitive and inexpensive screening technique for cardiomyopathy. It can be per-
formed at the same time as conventional 12-lead ECG, using the exact same equipment.
Although HF QRS ECG is highly sensitive for cardiomyopathy, its specificity may be com-
promised in patients with cardiac pathologies other than cardiomyopathy, such as
uncomplicated coronary artery disease. Further studies are required to determine the
usefulness of HF QRS for monitoring cardiomyopathy in a longitudinal fashion.
1126-117 Whole-Body Electrical Bioimpendance Is Accurate in 
Noninvasive Determination of Cardiac Output: A 
Thermodilution Controlled, Prospective, Double-Blind 
Evaluation
Guillermo Torre-Amiot, Gad Cotter, Edo Kaluski, Christoph Richter, Olga Milo, Ahmed 
Salah, Zvi Vered, Karl Stangl, Baylor College of Medicine, Houston, TX, Assaf-Harofeh 
Medical Center, Zerifin, Israel
Background: The NICaSTM is a novel non-invasive apparatus based on whole body
electrical bio-impedance for simple non-invasive continuous CO determination.
Patients and Methods: Patients were recruited while randomized in a study evaluating
the efficacy of Tezosentan (a ET-A/B endothelin antagonist) in patients admitted due to
acute heart failure (CHF). Patients were randomized after having been hospitalized due
to acute heart failure with dyspnea at rest, CI < 2.5 L/min/m2 and PCWP > 20 mmHg.
Study Protocol: At baseline and during treatment with study drug at the pre-specified
time points of 0.5,1,2,3,4 and 6 hours from randomization CO was determined by both
thermodilution and the NICaSTM 2001 apparatus. At each time point CO was determined
by thermodilution and NICaSTM 2001 apparatus by a two independed, blinded operators.
Results: Out of 130 patients enrolled, in 93 CO was measured simultaneously by both
methods at all the pre-determined time points. The overall Correlation between the two
methods was R=0.81. Precision and bias were 0.01±0.6 L/min. There was a difference
between the two methods in cardiac output readings. When Mean CI (of both methods)
was < 2 L/min/M2 CO readings were statistically significantly lower by NICaS while when
CI was >3 L/min/M2, CO readings were statistically significantly higher by NICaS. We
have calculated the cardiac power index (Cpi=CI* mean arterial pressure), and found that
low Cpi (indicating reduced myocardial contractile reserve) was related to higher recur-
rent CHF. However, Cpi based no NICaS CI measurement (NICaS Cpi) was a better pre-
dictor of recurrent CHF then thermodilution Cpi (Th Cpi), due to less accurate prediction
in patients with high Cpi.
Conclusions: NICaS is a novel accurate non-invasive method for CO determination. The
results of the present study suggest that NICaS is probably at least as accurate then
thermodilution for CO determination.
1126-118 Limitations of Exercise Cardiopulmonary Testing to 
Predict Heart Failure Prognosis in the Beta Blocker Era
Carl J. Lavie, Mandeep R. Mehra, Richard V. Milani, Hector O. Ventura, Ochsner Clinic 
Foundation, New Orleans, LA
Background: Studies from the pre-beta blocker era indicated that exercise cardiopulmo-
nary tests (CPX) predict prognosis in chronic systolic heart failure (HF). However, recent
studies have questioned the usefulness of these data for predicting prognosis in patients
treated with beta blockers.
Methods: We performed CPX in 209 consecutive patients in 1996 with mild – moderate
HF (mean EF 23%) followed for 19 ± 12 months for major clinical events (13 cardiac
deaths and 15 urgent transplantations) and assessed the prognostic impact of standard
CPX data in 64 patients treated with beta blockers (event rate 12.5%) and in 145 patients
not receiving beta blockers (event rate 13.8%).
Results: Both groups were similar for peak VO2, and peak VO2 corrected for lean body
weight, but patients on beta blockers had higher O2 pulse (11.0 ± 3.9 vs. 10.0 ± 4.0 ml/
beat; p=0.04) and O2 pulse lean (16.4 ± 6.0 vs. 14.4 ± 6.2ml/beat; p=0.02) which may be
important since O2 pulse lean was the strongest independent predictor of event-free sur-
vival (chi-square 12.4; p<0.001). Standard CPX data predicted prognosis considerably
better in patients not taking beta blockers compared with those on beta blockers (table).
However, in patients on beta blockers, peak VO2 of 14 ml/kg/min provided particularly
poor prognostic stratification and peak O2-pulse lean (cut-off 14 ml/beat) provided the
best prognostic stratification.
Conclusion: Standard CPX data need further refinement for providing risk stratification
for HF in the beta-blocker era.
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1127-103 Diastolic Dysfunction in Children and Young Adults 
With Marfan Syndrome
Bibhuti B. Das, Amy Taylor, Anji T. Yetman, University of Colorado Health Science 
Center/The Children's Hospital, Denver, CO
Background: Recent evidence suggests that adults with Marfan syndrome (MFS) have
diastolic dysfunction due to abnormal elastic recoil of the fibrillin-containing myocardial
interstitium. We sought to assess diastolic function in a large group of children and young
adults with MFS in order to determine whether diastolic dysfunction is present in all
patients or it is an age-related phenomenon.We also sought to assess the relationship
between % predicted aortic root size and the diastolic performance. Methods: Echocar-
diographic review of all 40 patients with MFS diagnosed in accordance with the revised
Gent criteria was performed. The last echocardiogram performed prior to initiation of car-
diac medical therapy was analyzed. Patients with more than trivial mitral or aortic regurgi-
tation, or with prior cardiovascular surgical intervention were excluded from the study.
Echocardiograms on a group of 40 age-matched normal controls with no family history of
MFS were used for comparison. The correlation between % predicted left ventricular end
diastolic diameter [LVEDd], % predicted aortic root size, and diastolic parameters [mitral
valve (MV) inflow: MV E/A, MV deceleration time (DT), and isovolumic relaxation time
(IVRT)] were determined. Results: There was no difference in age (yr) (17.4 ± 11.7 vs
13.9 ± 9.0, p= 0.14), sex (male 60% vs 50%, p= 0.38) or body surface area (1.47 ± 0.38
vs 1.33 ± 0.39, p= 0.09) between MFS patients and controls. Patients with MFS had sig-
nificantly impaired diastolic performance with both impaired relaxation and increased wall
stiffness as evidenced by prolonged DT (175 ± 69.2 ms vs 142 ± 27.5 ms, p= 0.007) &
IVRT (72 ± 23 ms vs 54 ± 11 ms, p = 0.0003). MV E (81± 23 ms), MV A (45± 10 ms), and
MV E/A (1.8 ± 0.6 ms) in MFS patients were within normal limits. There was no relation-
ship between % predicted aortic root size or % LVEDd and diastolic performance (for MV
E/A, r = 0.26 and 0.03; for IVRT, r = 0.13 and 0.17; and for DT, r = 0.09 and 0.06). Con-
clusion: Diastolic dysfunction is a clinical feature of MFS even in a younger cohort of
patients. Impairment of diastolic function may be secondary to abnormal myocardial elas-
tic recoil or altered afterload conditions in the face of increased aortic wall stiffness.
1127-104 Evaluation of Electrocardiography, Signal Averaged 
Electrocardiography, Exercise Tolerance Testing, 
Echocardiography and Magnetic Resonance Imaging in 
Diagnosis of Arrhythmogenic Right Ventricular 
Dysplasia
Darshan Dalal, Chandra Bomma, Khurram Nasir, Harikrishna Tandri, Cynthia James, 
Crystal Tichnell, Daniyal Ahmed, Hugh Calkins, Johns Hopkins University School of 
Medicine, Baltimore, MD
Background: Electrocardiography (ECG), signal averaged ECG (SAECG), exercise tol-
erance testing (ETT) Holter monitoring (Hol) and magnetic resonance imaging (MRI) are
commonly employed in the evaluation of patients suspected of having ARVD. Each of
these is widely available with the exception of MRI. We sought to determine if MRI pro-
vided incremental information to that obtained with the more widely available tests.
Methods: We evaluated 58 (26 male) patients referred for evaluation of possible ARVD.
Each patient underwent ECG, SAECG, ETT, Hol and MRI. Each test was rated as posi-
tive or negative for ARVD. The diagnosis of ARVD was established by International Task
Force Criteria. The sensitivity (Se) and specificity (Sp) for each test was calculated.
Receiver operating curve (ROC) analysis was used to evaluate the combination of ECG,
SAECG, Hol and ETT and their combination with MRI.
Results: The ECG (Se=96% Sp=78%) showed maximum utility in diagnosis of ARVD as
compared to SAECG (Se=22% Sp=94%), ETT (Se=22% Sp=88%), Hol (Se=67%
Predicting Major Clinical Events
Peak Variable Beta Blocker 
(n=64; 8 
events)
P-Value No Beta 
Blocker 
(n=145; 20 
events)
P-Value
VO2 >= 14 ml/kg/min 4/40 (10%) =0.48 6/83 (7%) =0.01
VO2 < 14 ml/kg/min 4/24 (17%) 14/62 (23%)
VO2 lean >= 19 ml/kg/min 3/39 (8%) =0.18 4/85 (5%) <0.001
VO2 lean < 19 ml/kg/min 5/25 (20%) 16/60 (27%)
O2 pulse >= 10 ml/beat 4/44 (9%) =0.26 5/75 (6%) =0.01
O2 pulse < 10 ml/beat 4/20 (20%) 15/70 (21%)
O2 pulse lean >= 14 ml/beat 3/41 (7%) =0.10 2/72 (3%) <0.0001
O2 pulse lean < 14 ml/beat 5/23 (22%) 18/73 (25%)
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Sp=61%) and MRI (Se=56% Sp=92%). ROC analysis showed that, in comparison to the
combination of ECG, SAECG, Hol and ETT, the area under the curve did not differ signif-
icantly for their combination with MRI.
Conclusion: This study demonstrates that an ECG offers the highest sensitivity and the
SAECG offers the highest specificity in diagnosing ARVD. MRI offers high specificity but
its combination with the ECG, SAECG, ETT and Hol does not improve the utility of the
other tests significantly. 
1127-105 Transient Left Ventricular Apical Ballooning Syndrome: 
A US Case-Series
Kevin A. Bybee, Abihiram Prasad, Gregory W. Barsness, Joseph G. Murphy, Allan S. 
Jaffe, Amir Lerman, R. Scott Wright, Charanjit S. Rihal, Mayo Clinic and Foundation, 
Rochester, MN
Background: Transient left ventricular apical ballooning syndrome (TLVABS) is a distinct
form of acute reversible left ventricular dysfunction which was initially described in Japan.
It’s frequency and clinical presentation in the U.S. is unclear. This is one of the first
descriptions of the syndrome in a U.S. population.
Methods: We identified 10 patients during the year 2002 who had: 1) apical LV ballooning
with akinesis or dyskinesis extending beyond a single major coronary artery distribution;
2) a coronary angiogram revealing no stenosis greater than 70%; 3) new ST segment/T
wave changes on the presenting electrocardiogram. We investigated the clinical charac-
teristics and short-term outcome of these patients with TLVABS.
Results: All patients were white females; mean age 71.5+12.0 years. Presenting symp-
toms were chest pain in 5, dyspnea in 3, and chest pain and dyspnea in 2 patients. Eight
had at least 1 mm of ST elevation in contiguous leads, typically V2-V5. The QTc was >
500ms in seven patients with a mean QTc of 519 ms+50 ms for all patients. All patients
had troponin T and/or CK-MB elevations. The highest recorded median peak troponin T
and CK-MB values were 0.59 ng/ml (25th-75th percentile 0.33-0.93 ng/ml) and 14.1ng/ml
(9.7-26.9 ng/ml), respectively. An identifiable preceding acute emotional or physiologic
stressor was present in 8 of 10 patients. All coronary stenosis in patients with CAD were
< 50%, except for 1 patient with a chronic 60% mid-LAD lesion. The mean LVEF at
admission was 44.8+10.2%, which improved to 58.4+11.9% at follow-up (22+41 days);
p=0.004. All 7 patients with available follow-up had resolution of wall motion abnormali-
ties (29+45 days). Five patients developed left heart failure requiring treatment. All
patients were alive at a median follow-up of 6.5 months (range 1-17 months).
Conclusion: This is one of the first series reporting TLVABS in a US population. TLVABS
can mimic AMI with ECG changes, elevation of cardiac biomarkers, associated left ven-
tricular dysfunction and in some, clinical heart failure. The short-term prognosis appears
favorable with resolution of LV dysfunction. Further studies including long-term follow-up
are needed.
1127-106 Usefulness of Tissue Doppler Imaging for Evaluating 
Systolic and Diastolic Left Ventricular Function in 
Patients With Primary Cardiac Amyloidosis
Jing Ping Sun, John A. Sallach, Neil L. Greenberg, William J. Stewart, Gordan Srkalovic, 
James D. Thomas, Allan L. Klein, The Cleveland Clinic Foundation, Cleveland, OH
Background: Cardiac amyloidosis is associated with increased left ventricular (LV) wall
thickness, normal or decreased LV cavity size, and congestive heart failure (CHF) with
normal or mildly reduced LV ejection fraction. Aim:To clarify whether tissue Doppler
imaging at multiple left ventricular LV sites could help estimate LV systolic and diastolic
function in patients with primary amyloidosis. Methods and Results: Standard 2-D, Dop-
pler and tissue Doppler echocardiographic study was performed in 12 consecutive
patients with primary amyloidosis confirmed by biopsy and 12 matched (age 62±14, 8
males in both groups) normal volunteers. The data were on-line or off-line analyzed using
Vivid 7, GE and Echo Pac. The parameters are present average segmental values as
mean±SD, T test was used for comparison. The diastolic functions of patients with pri-
mary amyloidosis were abnormal (6 were relaxation impaired; 3 were seudonormal; and
4 were restrictive). Tissue Doppler data were different between three types, but not sig-
nificantly; which may due to limited cases number. 
IST=interventricular septal thickness, PWT=LV posterior wall thickness, LV EF=LV ejec-
tion fraction. TK=myocardial displacement, STRs=systolic strain rate, STR=strain rate.
Conclusion: Cardiac amyloidosis is charaterized.by an early impaired in systolic and 
diastolic function. These abnormalities precedes the onset of congestive heart failure 
and can be detected by tissue Doppler velocity, displacement, strain rate and strain 
1127-107 Different Criteria of Cardiac Resynchronization Therapy 
Have Different Prognostic Value for Worsening Heart 
Failure or Major Arrhythmic Events in Idiopathic Dilated 
Cardiomyopathy
Laurent Fauchier, Julien Douglas, Dominique Babuty, Olivier Marie, Pierre Cosnay, Pierre 
Bonnet, Jean Paul Fauchier, Centre Hospitalier Universitaire Trousseau, Tours, France
Cardiac resynchronization therapy (CRT) with biventricular pacing (biV) improves cardiac
symptoms in heart failure patients with dilated cardiomyopathy. There are still controver-
sies about pertinent criteria for CRT and about prophylactic indications of biV cardio-
verter defibrillator.
Methods. In 201 patients with idiopathic dilated cardiomyopathy (IDC) in sinus rhythm
(WHO criteria; age 51±12 years; left ventricular ejection fraction 32±12%), the relative
risk of 1) cardiac death due to heart failure or heart transplantation and 2) sudden death
or sustained ventricular tachycardia (VT) or fibrillation (VF) were calculated separately
according to the inclusion criteria in the MUSTIC, InSync, MIRACLE and CONTAK stud-
ies.
Results. The percentage of patients meeting the inclusion criteria was respectively 6%
for MUSTIC, 7.5 % for InSync, 10 % for MIRACLE and 23 % for CONTAK. With a follow-
up of 51±42 months, 28 patients suffered cardiac death (15 progressive CHF, 13 sudden
deaths), 20 underwent heart transplantation and 12 had sustained VT/VF. Relative risks
of events are in table. Major arrhythmic events were 16 % of all the cardiac events for the
MUSTIC patients, 11% for InSync, 36 % for MIRACLE and 42 % for CONTAK.
Conclusion. In IDC, the patients with the less restrictive inclusion criteria of CRT had the
highest risk of major arrhythmic events. By contrast, severe HF patients with the MUSTIC
criteria of CRT mainly had a risk of worsening heart failure and may not benefit from biV
cardiverter defibrillator.
1127-108 Characteristics of Takotsubo Cardiomyopathy: First US 
Population-Based Report
Amish J. Desai, Milind R. Dhond, Mary Rose Fabi, Richard J. Valente, Ezra A. 
Amsterdam, University of California, Davis, Sacramento, CA
Background: Takotsubo Cardiomyopathy (TC) has been previously described in the Jap-
anese and more recently European literature.This is the first report of this condition in a
US population. TC is characterized by (1) suspected acute MI based on symptoms, elec-
trocardiographic (ECG) changes, and increased cardiac serum markers; (2) hyokinesis/
akinesis of mid to apical left ventricle (LV) and hyperkinesis of the basal LV on ventricu-
lography, (3) < 75% stenoses in the major coronary arteries, and (4) improvement of LV
function on follow-up.
Methods: From January 2002-August 2003 we admitted 9 patients with features consis-
tent with TC. All patients met all 4 criteria for the diagnosis of TC. Data on prestentation
included patient characteristics, complete hemodynamic assessment, coronary and LV
angiography and echocardiography.
Results: Mean patient age was 60.5 years, and 6 were women (66%). Cardiac risk fac-
tors: 7/9 (78%) had hypertension, 2/9 (22%) had diabetes, 2/9 (22%) were smokers, 2/9
(22%) had a family history of premature coronary heart disease, and 3/9 (33%) had
treated hypothyroidism. ECG revealed ST elevation in 3/9 (33%), and T wave changes in
6/9 (66%). At presentation, mean ejection fraction was 32.5%, mean wedge pressure
was 12.7 mm Hg and cardiac output of 3.14 L/min. 8/9 (88%) patients had physiologic
stressors at the time of presentation with 1/9 having an intense emotional stressor. Coro-
nary angiography was normal in all patients and left ventriculography revealed the char-
acteristic Takotsubo (octopus trap) shape. At a mean follow-up of 6 + 2 months all
patients were alive with a mean EF of 49%.
Conclusions: Takotsubo Cardiomyopathy is an unusual and probably underdiagnosed
entity. Our data from the first American cohort confirm prior reports of a clinical presenta-
Standard 
Echo LVD(cm) IST(cm) PWT(c
m)
 EF(%)
LAarea 
(cm2) DT(msec) E/Amitral
Normal 4.7±0.6 1.0±0.2 1.0±0.2 64±7 16±4 201±28 1.2±0.5
Amyoloid 4.0±0.7 1.8±0.2 1.7±0.4 57±3 25±7 167±54 1.9±1.0
p 0.02 <0.0001 <0.0001 0.02 <0.0001 0.10 0.12
Tissue 
Doppler 
Echo
LVS 
velocity(cm/
sec)
LV 
velocityE/
A
LVTK(c
m)
STRs(1/
s)
LV 
STRE/A
LV Systolic 
Strain (%) LV 
StrainE/
A
Normal 4.5±1.0 1.9±1.2 0.8±0.2 -1.1±0.3 1.6±0.4 -19±4 1.6±1.1
Amyoloid 3.0±1.4 4.4±1.9 0.4±0.2 -0.8±0.4 3.5±3.2 -10±5 2.7±0.8
p 0.01 0.01 <0.0001 0.02 0.04 <0.0001 0.01
NYH
A
LV EDD LV EF QRS RR (95% CI) HF 
events
p RR (95% CI) 
Arrhythmic events
p
MUSTIC III >60 mm <35 % >150 ms 4.63 (1.76-12.19) 0.0019 1.16 (0.15-8.70) 0.89
InSync III-IV >60 mm <35 % >150 ms 4.27 (1.85-9.90) 0.0007 1.45 (0.19-11.10) 0.72
MIRACLE III-IV >55 mm <35 % >130 ms 3.14 (1.41-6.99) 0.005 1.83 (0.63-5.35) 0.55
CONTAK II-IV <35 % >120 ms 3.67 (1.85-7.29) 0.0002 2.65 (1.19-5.95) 0.018
